nodes	percent_of_prediction	percent_of_DWPC	metapath
Indapamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Indapamide—Vaginal infection—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Indapamide—Erythema—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Indapamide—Malnutrition—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Indapamide—Cough—Bleomycin—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Indapamide—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Indapamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Indapamide—Chest pain—Bleomycin—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Indapamide—Myalgia—Bleomycin—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Indapamide—Back pain—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Indapamide—Discomfort—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Indapamide—Urine output increased—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Indapamide—Bladder pain—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Indapamide—Ecchymosis—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Indapamide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Indapamide—Vision blurred—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Indapamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Indapamide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Indapamide—Oedema—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Indapamide—Erythema—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Indapamide—Infection—Bleomycin—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Indapamide—Anaemia—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Indapamide—Back pain—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Indapamide—Vomiting—Teniposide—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Indapamide—Agitation—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Indapamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Indapamide—Asthenia—Fludarabine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Indapamide—Rash—Teniposide—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Indapamide—Dermatitis—Teniposide—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Indapamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Indapamide—Headache—Teniposide—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Indapamide—Pruritus—Fludarabine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Indapamide—Back pain—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Indapamide—Leukopenia—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Indapamide—Anorexia—Bleomycin—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Indapamide—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Indapamide—Anaemia—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Indapamide—Agitation—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Indapamide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Indapamide—Photosensitivity—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Indapamide—Polyuria—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Indapamide—Hypotension—Bleomycin—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Indapamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Indapamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Indapamide—Nausea—Teniposide—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Indapamide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Indapamide—Vertigo—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Indapamide—Hepatic failure—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Indapamide—Leukopenia—Vincristine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Indapamide—Chest pain—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Indapamide—Myalgia—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Indapamide—Anxiety—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Indapamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Indapamide—Malaise—Mitoxantrone—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Indapamide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Indapamide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Indapamide—Oedema—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Indapamide—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Indapamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Indapamide—Myalgia—Vincristine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Indapamide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Indapamide—Cough—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Indapamide—Infection—Carmustine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Indapamide—Vomiting—Fludarabine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Indapamide—Rash—Fludarabine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Indapamide—Dermatitis—Fludarabine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Indapamide—Pain—Bleomycin—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Indapamide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Indapamide—Headache—Fludarabine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Indapamide—Tachycardia—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Indapamide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Indapamide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Indapamide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Indapamide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Indapamide—Lethargy—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Indapamide—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Indapamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Indapamide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Indapamide—Oedema—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Indapamide—Anorexia—Carmustine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Indapamide—Infection—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Indapamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Indapamide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Indapamide—Nervous system disorder—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Indapamide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Indapamide—Hypotension—Carmustine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Indapamide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Indapamide—Oedema—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Indapamide—Nausea—Fludarabine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Indapamide—Infection—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Indapamide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Indapamide—Shock—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Indapamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Indapamide—Urticaria—Bleomycin—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Indapamide—Anorexia—Vincristine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Indapamide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Indapamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Indapamide—Insomnia—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Indapamide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Indapamide—Irritability—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Indapamide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Indapamide—Paraesthesia—Carmustine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Indapamide—Hypotension—Vincristine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Indapamide—Dyspnoea—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Indapamide—Somnolence—Carmustine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Indapamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Indapamide—Ataxia—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Indapamide—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Indapamide—Decreased appetite—Carmustine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Indapamide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Indapamide—Insomnia—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Indapamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Indapamide—Paraesthesia—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Indapamide—Pain—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Indapamide—Constipation—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Indapamide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Indapamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Indapamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Indapamide—Decreased appetite—Vincristine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Indapamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Indapamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Indapamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Indapamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Indapamide—Fatigue—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Indapamide—Asthenia—Bleomycin—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Indapamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Indapamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Indapamide—Constipation—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Indapamide—Pain—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Indapamide—Asthma—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Indapamide—Pruritus—Bleomycin—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Indapamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Indapamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Indapamide—Pancreatitis—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Indapamide—Constipation—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Indapamide—Pain—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Indapamide—Abdominal pain—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Indapamide—Body temperature increased—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Indapamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Indapamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Indapamide—Dysuria—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Indapamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Indapamide—Abdominal pain—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Indapamide—Body temperature increased—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Indapamide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Indapamide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Indapamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Indapamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Indapamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Indapamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Indapamide—Pneumonia—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Indapamide—Vomiting—Bleomycin—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Indapamide—Drowsiness—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Indapamide—Depression—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Indapamide—Rash—Bleomycin—lymphatic system cancer	0.001	0.001	CcSEcCtD
Indapamide—Dermatitis—Bleomycin—lymphatic system cancer	0.001	0.001	CcSEcCtD
Indapamide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000999	0.000999	CcSEcCtD
Indapamide—Asthenia—Carmustine—lymphatic system cancer	0.000996	0.000996	CcSEcCtD
Indapamide—Renal failure—Methotrexate—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Indapamide—Stomatitis—Methotrexate—lymphatic system cancer	0.000982	0.000982	CcSEcCtD
Indapamide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Indapamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000976	0.000976	CcSEcCtD
Indapamide—Sweating—Methotrexate—lymphatic system cancer	0.000966	0.000966	CcSEcCtD
Indapamide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000953	0.000953	CcSEcCtD
Indapamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00095	0.00095	CcSEcCtD
Indapamide—Asthenia—Vincristine—lymphatic system cancer	0.00095	0.00095	CcSEcCtD
Indapamide—Diarrhoea—Carmustine—lymphatic system cancer	0.000949	0.000949	CcSEcCtD
Indapamide—Nausea—Bleomycin—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Indapamide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00094	0.00094	CcSEcCtD
Indapamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000926	0.000926	CcSEcCtD
Indapamide—Dizziness—Carmustine—lymphatic system cancer	0.000918	0.000918	CcSEcCtD
Indapamide—Diarrhoea—Vincristine—lymphatic system cancer	0.000906	0.000906	CcSEcCtD
Indapamide—Hepatitis—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Indapamide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Indapamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000893	0.000893	CcSEcCtD
Indapamide—Urethral disorder—Methotrexate—lymphatic system cancer	0.000887	0.000887	CcSEcCtD
Indapamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000883	0.000883	CcSEcCtD
Indapamide—Vomiting—Carmustine—lymphatic system cancer	0.000882	0.000882	CcSEcCtD
Indapamide—Dizziness—Vincristine—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Indapamide—Rash—Carmustine—lymphatic system cancer	0.000875	0.000875	CcSEcCtD
Indapamide—Dermatitis—Carmustine—lymphatic system cancer	0.000874	0.000874	CcSEcCtD
Indapamide—Visual impairment—Methotrexate—lymphatic system cancer	0.000872	0.000872	CcSEcCtD
Indapamide—Headache—Carmustine—lymphatic system cancer	0.000869	0.000869	CcSEcCtD
Indapamide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000855	0.000855	CcSEcCtD
Indapamide—Tinnitus—Methotrexate—lymphatic system cancer	0.000844	0.000844	CcSEcCtD
Indapamide—Vomiting—Vincristine—lymphatic system cancer	0.000842	0.000842	CcSEcCtD
Indapamide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00084	0.00084	CcSEcCtD
Indapamide—Rash—Vincristine—lymphatic system cancer	0.000835	0.000835	CcSEcCtD
Indapamide—Dermatitis—Vincristine—lymphatic system cancer	0.000834	0.000834	CcSEcCtD
Indapamide—Headache—Vincristine—lymphatic system cancer	0.00083	0.00083	CcSEcCtD
Indapamide—Nausea—Carmustine—lymphatic system cancer	0.000824	0.000824	CcSEcCtD
Indapamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00082	0.00082	CcSEcCtD
Indapamide—Rash—Mitoxantrone—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Indapamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Indapamide—Headache—Mitoxantrone—lymphatic system cancer	0.000808	0.000808	CcSEcCtD
Indapamide—Erythema—Methotrexate—lymphatic system cancer	0.000788	0.000788	CcSEcCtD
Indapamide—Malnutrition—Methotrexate—lymphatic system cancer	0.000788	0.000788	CcSEcCtD
Indapamide—Nausea—Vincristine—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Indapamide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000771	0.000771	CcSEcCtD
Indapamide—Nausea—Mitoxantrone—lymphatic system cancer	0.000766	0.000766	CcSEcCtD
Indapamide—Back pain—Methotrexate—lymphatic system cancer	0.000762	0.000762	CcSEcCtD
Indapamide—Vision blurred—Methotrexate—lymphatic system cancer	0.000742	0.000742	CcSEcCtD
Indapamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Indapamide—Anaemia—Methotrexate—lymphatic system cancer	0.000728	0.000728	CcSEcCtD
Indapamide—Malaise—Methotrexate—lymphatic system cancer	0.00071	0.00071	CcSEcCtD
Indapamide—Vertigo—Methotrexate—lymphatic system cancer	0.000708	0.000708	CcSEcCtD
Indapamide—Leukopenia—Methotrexate—lymphatic system cancer	0.000705	0.000705	CcSEcCtD
Indapamide—Cough—Methotrexate—lymphatic system cancer	0.000687	0.000687	CcSEcCtD
Indapamide—Arthralgia—Methotrexate—lymphatic system cancer	0.000671	0.000671	CcSEcCtD
Indapamide—Myalgia—Methotrexate—lymphatic system cancer	0.000671	0.000671	CcSEcCtD
Indapamide—Chest pain—Methotrexate—lymphatic system cancer	0.000671	0.000671	CcSEcCtD
Indapamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000666	0.000666	CcSEcCtD
Indapamide—Discomfort—Methotrexate—lymphatic system cancer	0.000662	0.000662	CcSEcCtD
Indapamide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Indapamide—Infection—Methotrexate—lymphatic system cancer	0.000639	0.000639	CcSEcCtD
Indapamide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00063	0.00063	CcSEcCtD
Indapamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000629	0.000629	CcSEcCtD
Indapamide—Skin disorder—Methotrexate—lymphatic system cancer	0.000624	0.000624	CcSEcCtD
Indapamide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000621	0.000621	CcSEcCtD
Indapamide—Anorexia—Methotrexate—lymphatic system cancer	0.000613	0.000613	CcSEcCtD
Indapamide—Hypotension—Methotrexate—lymphatic system cancer	0.000601	0.000601	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000586	0.000586	CcSEcCtD
Indapamide—Insomnia—Methotrexate—lymphatic system cancer	0.000581	0.000581	CcSEcCtD
Indapamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000577	0.000577	CcSEcCtD
Indapamide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000573	0.000573	CcSEcCtD
Indapamide—Somnolence—Methotrexate—lymphatic system cancer	0.000571	0.000571	CcSEcCtD
Indapamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000566	0.000566	CcSEcCtD
Indapamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000559	0.000559	CcSEcCtD
Indapamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000555	0.000555	CcSEcCtD
Indapamide—Fatigue—Methotrexate—lymphatic system cancer	0.000554	0.000554	CcSEcCtD
Indapamide—Pain—Methotrexate—lymphatic system cancer	0.00055	0.00055	CcSEcCtD
Indapamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00053	0.00053	CcSEcCtD
Indapamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000526	0.000526	CcSEcCtD
Indapamide—Urticaria—Methotrexate—lymphatic system cancer	0.000511	0.000511	CcSEcCtD
Indapamide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000508	0.000508	CcSEcCtD
Indapamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000508	0.000508	CcSEcCtD
Indapamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000474	0.000474	CcSEcCtD
Indapamide—Asthenia—Methotrexate—lymphatic system cancer	0.000461	0.000461	CcSEcCtD
Indapamide—Pruritus—Methotrexate—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Indapamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.00044	0.00044	CcSEcCtD
Indapamide—Dizziness—Methotrexate—lymphatic system cancer	0.000425	0.000425	CcSEcCtD
Indapamide—Vomiting—Methotrexate—lymphatic system cancer	0.000409	0.000409	CcSEcCtD
Indapamide—Rash—Methotrexate—lymphatic system cancer	0.000405	0.000405	CcSEcCtD
Indapamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000405	0.000405	CcSEcCtD
Indapamide—Headache—Methotrexate—lymphatic system cancer	0.000403	0.000403	CcSEcCtD
Indapamide—Nausea—Methotrexate—lymphatic system cancer	0.000382	0.000382	CcSEcCtD
